I Mab (IMAB)

NASDAQ
11.30
+0.42(+3.86%)
Pre Market
12.00
+0.70(+6.19%)
- Real-time Data
  • Volume:
    522,525
  • Day's Range:
    10.33 - 11.30
  • 52 wk Range:
    8.05 - 84.05

IMAB Overview

Prev. Close
10.88
Day's Range
10.33-11.3
Revenue
88.02M
Open
10.65
52 wk Range
8.05-84.05
EPS
-4.57
Volume
522,525
Market Cap
932.77M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,308,861
P/E Ratio
-
Beta
-
1-Year Change
-86.54%
Shares Outstanding
82,545,693
Next Earnings Date
Sep 05, 2022
What is your sentiment on I Mab?
or
Market is currently closed. Voting is open during market hours.

I Mab News

I Mab Company Profile

I Mab Company Profile

Employees
378

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell
  • benzinga.com/analyst-ratings/analyst-color/21/03/20169471/i-mab-poised-to-capitalize-on-growing-oncology-sector-needham-says-in-bullish-initi
    0
    • should be going up!!!!
      0
      • hi
        0
    • any news here?
      0
      • R u guys ready to invest?
        0
        • China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone DeficiencyThe news about IMAB.
          0
          • I am waiting the news about Covid-19 treatment!!
            0